wherein D is $-OCH_2CH_2N(R_3)R_4$ (R_3 and R_4 either being independently selected from the group consisting of C_1-C_4 alkyl, or R_3, R_4 and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1-pyrrolidino, methyl-1pyrrolidinyl, piperidino, hexamethyleneimino[,] and morpholino[, ring).]); and

wherein R_1 and R_2 are independently selected from the group consisting of: hydrogen, hydroxyl, and a moiety converted in vivo in hydroxyl.

C1

64. (Amended) The method of Claim 40 wherein the selective estrogen receptor modulator is an indole derivative compound of the following formula:



wherein D is $-OCH_2CH_2N(R_3)R_4$ (R_3 and R_4 either being independently selected from the group consisting of C_1-C_4 alkyl, or R_3, R_4 and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1-pyrrolidino, methyl-1pyrrolidinyl, piperidino, hexamethyleneimino[,] and morpholino[, ring).]); and

wherein R_1 and R_2 are independently selected from the group consisting of: hydrogen, hydroxyl, and a moiety converted in vivo in hydroxyl.

65. (Amended) The method of Claim 41 wherein the selective estrogen receptor modulator is an indole derivative compound of the following formula:



wherein D is $-OCH_2CH_2N(R_3)R_4$ (R_3 and R_4 either being independently selected from the group consisting of C_1-C_4 alkyl, or R_3, R_4 and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1-pyrrolidino, methyl-1pyrrolidinyl, piperidino, hexamethyleneimino[,] and morpholino[, ring).]; and

wherein R_1 and R_2 are independently selected from the group consisting of: hydrogen, hydroxyl, and a moiety converted in vivo in hydroxyl.

66. (Amended) The method of Claim 39 wherein the selective estrogen receptor modulator is a centchroman derivative compound of the following formula:



wherein R_1 and R_2 are independently selected from the group consisting of: hydrogen, hydroxyl, and moiety converted in vivo in hydroxyl;

wherein R_5 and R_6 are independently hydrogen or C_1-C_6 alkyl;

wherein D is $-OCH_2CH_2N(R_3)R_4$ (R_3 and R_4 either being independently selected from the group consisting of C_1-C_4 alkyl, or R_3, R_4 and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1-pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino[,] and morpholino[, ring)].

67. (Amended) The method of Claim 40 wherein the selective estrogen receptor modulator is a centchroman derivative compound of the following formula:



wherein R_1 and R_2 are independently selected from the group consisting of: hydrogen, hydroxyl, and moiety converted in vivo in hydroxyl;

wherein R_5 and R_6 are independently hydrogen or C_1-C_6 alkyl;

wherein D is $-OCH_2CH_2N(R_3)R_4$ (R_3 and R_4 either being independently selected from the group consisting of C_1-C_4 alkyl, or R_3, R_4 and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1-pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino[,] and morpholino[, ring)].

68. (Amended) The method of Claim 41 wherein the selective estrogen receptor modulator is a centchroman derivative compound of the following formula:



C1

wherein R_1 and R_2 are independently selected from the group consisting of: hydrogen, hydroxyl, and moiety converted in vivo in hydroxyl;

wherein R_5 and R_6 are independently hydrogen or C_1-C_6 alkyl;

wherein D is $-OCH_2CH_2N(R_3)R_4$ (R_3 and R_4 either being independently selected from the group consisting of C_1-C_4 alkyl, or R_3, R_4 and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1-pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino[,] and morpholino[, ring)].

78. (Amended) The method of Claim 75, wherein the compound is a benzopyran derivative of the following general structure:

C2



wherein D is $-OCH_2CH_2N(R_3)R_4$ (R_3 and R_4 either being independently selected from the group consisting of C_1-C_4 alkyl, or R_3, R_4 and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1-pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino[,] and morpholino[, ring).]); and

wherein $R_1$and R_2 are independently selected from the group consisting of: hydrogen, hydroxyl, and a moiety converted in vivo in hydroxyl.

79. (Amended) The method of Claim 76, wherein the compound is a benzopyran derivative of the following general structure:



wherein D is $-OCH_2CH_2N(R_3)R_4$ (R_3 and R_4 either being independently selected from the group consisting of C_1-C_4 alkyl, or R_3, R_4 and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1-pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino[,] and morpholino[, ring).]); and

wherein $R_1$and R_2 are independently selected from the group consisting of: hydrogen, hydroxyl, and a moiety converted in vivo in hydroxyl.

80. (Amended) The method of Claim 77, wherein the compound is a benzopyran derivative of the following general structure:



wherein D is $-OCH_2CH_2N(R_3)R_4$ (R_3 and R_4 either being independently selected from the group consisting of C_1-C_4 alkyl, or R_3, R_4 and the nitrogen atom to which they are bound, together being a ring structure selected from the group consisting of pyrrolidino, dimethyl-1-pyrrolidino, methyl-1-pyrrolidinyl, piperidino, hexamethyleneimino[,] and morpholino[, ring).]); and

wherein $R_1$and R_2 are independently selected from the group consisting of: hydrogen, hydroxyl, and a moiety converted in vivo in hydroxyl.

81. (Amended) The method of Claim 78, wherein the benzopyran derivative is an optically active compound having an absolute configuration S on carbon 2 or [pharamaceutically] pharmaceutically acceptable salt thereof, said compound having the molecular structure:



wherein R_1 and R_2 are independently selected from the group consisting of hydroxyl and an moiety convertible *in vivo* to hydroxyl;

wherein R^3 is a species selected from the group consisting of saturated, unsaturated or substituted pyrrolidinyl, saturated, unsaturated or substituted piperidino, saturated, unsaturated or substituted [piperidinly] piperidinyl, saturated, unsaturated or substituted morpholino, nitrogen-containing cyclic moiety, nitrogen-containing polycyclic moiety, and NRaRb (Ra and Rb being independently hydrogen, straight or branched C_1-C_6 alkyl, straight or branched C_2-C_6 alkenyl, and straight or branched C_2-C_6 alkynyl).

82. (Amended) The method of Claim79, wherein the benzopyran derivative is an optically active compound having an absolute configuration S on carbon 2 or [pharamaceutically] pharmaceutically acceptable salt thereof, said compound having the molecular structure:

C2



wherein R_1 and R_2 are independently selected from the group consisting of hydroxyl and an moiety convertible *in vivo* to hydroxyl;

wherein R^3 is a species selected from the group consisting of saturated, unsaturated or substituted pyrrolidinyl, saturated, unsaturated or substituted piperidino, saturated, unsaturated or substituted [piperidinly] piperidinyl, saturated, unsaturated or substituted morpholino, nitrogen-containing cyclic moiety, nitrogen-containing polycyclic moiety, and NRaRb (Ra and Rb being independently hydrogen, straight or

branched C_1-C_6 alkyl, straight or branched C_2-C_6 alkenyl, and straight or branched C_2-C_6 alkynyl).

83. (Amended) The method of Claim 80, wherein the benzopyran derivative is an optically active compound having an absolute configuration S on carbon 2 or [pharamaceutically] pharmaceutically acceptable salt thereof, said compound having the molecular structure:



wherein R_1 and R_2 are independently selected from the group consisting of hydroxyl and an moiety convertible *in vivo* to hydroxyl;

wherein R^3 is a species selected from the group consisting of saturated, unsaturated or substituted pyrrolidinyl, saturated, unsaturated or substituted piperidino, saturated, unsaturated or substituted [piperidinly] piperidinyl, saturated, unsaturated or substituted morpholino, nitrogen-containing cyclic moiety, nitrogen-containing polycyclic moiety, and NRaRb (Ra and Rb being independently hydrogen, straight or branched C_1-C_6 alkyl, straight or branched C_2-C_6 alkenyl, and straight or branched C_2-C_6 alkynyl).

90. (Amended) The method of Claim 84 wherein the benzopyran derivative is a salt of an acid selected from the group consisting of acetic acid, adipic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, fumaric acid, hydroiodic acid, hydrobromic acid, hydrochloric acid, hydrochlorothiazide acid, hydroxy-naphthoic acid, lactic acid, maleic acid,

methanesulfonic acid, methylsulfuric acid, 1,5-naphthalenedisulfonic acid, nitric acid, palmitic acid, pivalic acid, phosphoric acid, propionic acid, succinic acid, sulfuric acid, tartaric acid, terephthalic aciD, p-toluenesulfonic [aciD] acid, and valeric acid.

91. (Amended) The method of Claim 85 wherein the benzopyran derivative is a salt of an acid selected from the group consisting of acetic acid, adipic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, fumaric acid, hydroiodic acid, hydrobromic acid, hydrochloric acid, hydrochlorothiazide acid, hydroxy-naphthoic acid, lactic acid, maleic acid, methanesulfonic acid, methylsulfuric acid, 1,5-naphthalenedisulfonic acid, nitric acid, palmitic acid, pivalic acid, phosphoric acid, propionic acid, succinic acid, sulfuric acid, tartaric acid, terephthalic aciD, p-toluenesulfonic [aciD] acid, and valeric acid.

92. (Amended) The method of Claim 86 wherein the benzopyran derivative is a salt of an acid selected from the group consisting of acetic acid, adipic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, fumaric acid, hydroiodic acid, hydrobromic acid, hydrochloric acid, hydrochlorothiazide acid, hydroxy-naphthoic acid, lactic acid, maleic acid, methanesulfonic acid, methylsulfuric acid, 1,5-naphthalenedisulfonic acid, nitric acid, palmitic acid, pivalic acid, phosphoric acid, propionic acid, succinic acid, sulfuric acid, tartaric acid, terephthalic aciD, p-toluenesulfonic [aciD] acid, and valeric acid.

96. (Amended) The method of Claim 2 wherein said selective estrogen receptor modulator is:

EM-1538



and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate[, androst-5-ene3β,17β-diol] and androst-5-ene-3β,17β-diol.

97. (Amended) The method of Claim 3 wherein said selective estrogen receptor modulator is:

EM-1538



and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate[, androst-5-ene3β,17β-diol] and androst-5-ene-3β,17β-diol.

98. (Amended) The method of Claim 4 wherein said selective estrogen receptor modulator is:

EM-1538